Survival data in elderly patients with locally advanced non-small cell lung cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Domingues, Pedro Masson ^a   Zylberberg, Ricardo ^a   Da Matta De Castro, Thalita ^a   Baldotto, Clarissa Seródio ^a   De Lima Araujo, Luiz Henrique ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Chemoradiotherapy; Elderly; Lung neoplasms; Survival

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84872020658     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0449-8     Document Type: Article

References (14)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Aupérin A, Le Péchoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17:473-83.
3. Auperin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-90.
4. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201-6.
5. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients (pts) with local advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol. 2002;21:75s (abstr 1193).
6. Okamoto H, Atagi S, Kawahara M, et al. Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. J Clin Oncol. 2012;30 (suppl; abstr 7017).
7. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975-2005/. Accessed 15 April 2012.
8. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc. 1958;53:457-81.
9. Lawless JS. Statistical models and methods for life-time data. New York: Wiley; 1982.
10. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
11. Davidoff AJ, Gardner JF, Seal B, et al. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(5):934-41.
12. Coate LE, Massey C, Hope A, et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(3):537-44.
13. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079-88.
14. Cavalcanti L, Kutwak F, Ruiz AL, et al. Outcomes of combined modality treatment in elderly patients with stage III non-small cell lung cancer. J Clin Oncol. 2012;30 (suppl; abstr 7049).